US Regenerative Medicine Companies

First ever gene therapy for Duchenne Muscular Dystrophy: Sarepta Therapeutics received FDA approval for SRP-9001 (ELEVIDYS), a gene therapy treatment for patients with Duchenne Muscular Dystrophy, marking a groundbreaking milestone in gene therapy applications.

Expansion of CAR-T therapy indications: KITE Pharma's Yescarta® received FDA approval for treating follicular lymphoma, opening up possibilities for CAR-T therapy in additional cancer types.

FDA grants Fast Track designation to stem cell therapy for osteoarthritis: Asterias Biotherapeutics secured Fast Track designation for its AST-004, a mesenchymal stem cell therapy candidate for treating knee osteoarthritis, potentially accelerating its development process.

Regenerative Medicine Ventures raises $300 million in Series B funding: This significant investment signifies growing investor confidence in the regenerative medicine market's potential.

Collaboration between CRISPR Therapeutics and Vertex Pharmaceuticals: The companies will jointly develop and commercialize gene editing therapies for sickle cell disease and beta-thalassemia, leveraging their combined expertise.

Establishment of new cell and gene therapy centers: Leading hospitals and research institutions are expanding their capabilities in cell and gene therapy, aiming to provide patients with access to these innovative treatments.

• 
  

  Biogen (US)

  
  


• 
  

  Sarepta Therapeutics, Inc. (US)

  
  


• 
  

  Gilead Sciences, Inc. (US)

  
  


• 
  

  Amgen, Inc. (US)

  
  


• 
  

  Vericel Corporation (US)

  
  


• 
  

  MiMedx (US)

  
  


• 
  

  Organogenesis Inc. (US)

  
  


• 
  

  Medtronic plc (US)

  
  


• 
  

  BioRestorative Therapies, Inc (US)

  
  


• 
  

  bluebird bio, Inc. (US)

  
  


• 
  

  Athersys, Inc. (US)